Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOS-448 Combinations in Advanced Solid Tumors
NCT05060432Phase 2Active, not recruiting
- Sponsor
- iTeos Therapeutics
- Start
- Sep 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of belrestotug in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more (9 arms), sponsored by iTeos Therapeutics. Primary endpoints: Percentage of participants with DLT and Adverse Events at 120 days, Recommended Phase 2 dose at 48 weeks and 1 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
belrestotug
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT05060432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060432.